5-methyl-9H-benzo[c]indolo[3,2,1-ij][1,5]naphthyridin-9-one

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吲哚萘啶生物碱
• 英文名称: 5-methyl-9H-benzo[c]indolo[3,2,1-ij][1,5]naphthyridin-9-one
• 英文别名: 5-methyl-1,11-diazapentacyclo[10.7.1.02,7.08,20.013,18]icosa-2(7),3,5,8(20),9,11,13,15,17-nonaen-19-one
• 化学式: C₁₉H₁₂N₂O
• 分子量: 284.3
• InChiKey: XSSWXIZSJLBKCA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] ARYL HYDROCARBON RECEPTOR ACTIVATORS<br/>[FR] ACTIVATEURS DU RÉCEPTEUR D'HYDROCARBURE ARYLE
  申请人：UNIV OREGON STATE

  公开号：WO2021022061A1

  公开（公告）日：2021-02-04

  Small molecule AhR ligands are disclosed. The ligands can induce the differentiation of Tr1 cells to suppress pathogenic immune responses without inducing nonspecific immune suppression. Methods of treatment of autoimmune diseases using the AhR ligands are also disclosed.

  披露了小分子AhR配体。这些配体可以诱导Tr1细胞分化，抑制病原免疫反应，而不引起非特异性免疫抑制。还披露了使用AhR配体治疗自身免疫疾病的方法。
• [EN] SELECTIVE INHIBITORS OF GENOTOXIC STRESS-INDUCED IKK/NF-kB PATHWAYS<br/>[FR] INHIBITEURS SÉLECTIFS DE VOIES IKK/NF-KB INDUITES PAR LE STRESS GÉNOTOXIQUE
  申请人：MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT

  公开号：WO2018087389A1

  公开（公告）日：2018-05-17

  The invention relates to chemical compounds and their use as a medicament in the treatment of a disease associated with genotoxic stress-induced I KK/NF-κΒ (NF-kappaB) activation, preferably in the treatment of a subject suffering from cancer exhibiting genotoxic stress-induced I KK/NF-κΒ activation. The invention further relates to a pharmaceutical composition comprising a compound of the invention for the treatment of a subject afflicted by a disease associated with genotoxic stress-induced I KK/NF-κΒ activation.

  这项发明涉及化合物及其作为药物在治疗与基因毒性应激诱导的I KK/NF-κΒ（NF-kappaB）激活相关疾病中的用途，优选用于治疗患有展现基因毒性应激诱导的I KK/NF-κΒ激活的癌症患者。该发明还涉及一种包含该发明化合物的药物组合物，用于治疗患有与基因毒性应激诱导的I KK/NF-κΒ激活相关疾病的患者。
• SELECTIVE INHIBITORS OF GENOTOXIC STRESS-INDUCED IKK/NF-KB PATHWAYS
  申请人：Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft

  公开号：EP3321264A1

  公开（公告）日：2018-05-16

  The invention relates to chemical compounds and their use as a medicament in the treatment of a disease associated with genotoxic stress-induced IKK/NF-κB (NF-kappaB) activation. The invention further relates to a pharmaceutical composition comprising a compound of the invention for the treatment of a subject afflicted by a disease associated with genotoxic stress-induced IKK/NF-κB activation.

  本发明涉及化合物及其在治疗与基因毒性应激诱导的 IKK/NF-κB（NF-kappaB）激活相关的疾病中作为药物的用途。本发明进一步涉及一种包含本发明化合物的药物组合物，用于治疗受基因毒性应激诱导的IKK/NF-κB活化相关疾病困扰的受试者。
• Selective inhibitors of gentotoxic steress-induced IKK/NF-κB pathways
  申请人：Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft

  公开号：US11028084B2

  公开（公告）日：2021-06-08

  A method is for treatment of a disease associated with genotoxic stress-induced inhibitor of nuclear factor-κB kinase/nuclear factor kappa-light chain enhancer of activated B cells (IKK/NF-κB) signaling. The method can include administering a compound to a subject having a cancer exhibiting genotoxic stress induced IKK/NF-κB activation.

  一种方法用于治疗与基因毒性应激诱导的核因子-κB激酶/活化B细胞的核因子卡巴轻链增强子（IKK/NF-κB）信号转导抑制有关的疾病。该方法可包括向患有基因毒性应激诱导的IKK/NF-κB活化的癌症的受试者施用一种化合物。
• SPECIFIC INHIBITORS OF PROTEIN P21 AS THERAPEUTIC AGENTS
  申请人：BADEN-WÜRTTEMBERG STIFTUNG GMBH

  公开号：US20150210717A1

  公开（公告）日：2015-07-30

  The present invention relates to novel inhibitors of p21. These inhibitors are useful as therapeutic agents for promot ing cell regeneration and in the treatment of cancer. Improvement of cell regeneration is particularly desirable in patients of old age or in patients suffering from chronic diseases, acute or chronic injuries.